Elmer Berghorn

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Jeffrey S. Weber, Geoff Gibney, Ryan J. Sullivan et al. · The Lancet Oncology · 2016 · 335 citations

Medicine, Oncology, Pharmacology +16

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

Daniel R. Budman, Neal J. Meropol, Bruno Reigner et al. · Journal of Clinical Oncology · 1998 · 259 citations

Medicine, Oncology, Pharmacology +17

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

David Cella, Viktor Grünwald, Paul Nathan et al. · The Lancet Oncology · 2016 · 218 citations

Medicine, Nephrology, Oncology +13

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xīn Gào, Howard A. Burris, Jacqueline Vuky et al. · Journal of Clinical Oncology · 2022 · 186 citations

Medicine, Oncology, Pharmacology +16

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff et al. · Journal for ImmunoTherapy of Cancer · 2018 · 180 citations · Full text

Medicine, Oncology, Pharmacology +17